Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 595Carcinoma, Renal Cell 276Urinary Bladder Neoplasms 175Kidney Neoplasms 112Neoplasms 101Neoplasm Metastasis 94Carcinoma, Non-Small-Cell Lung 94Carcinoma, Transitional Cell 86Melanoma 85Breast Neoplasms 83Ovarian Neoplasms 64Lung Neoplasms 50Colorectal Neoplasms 50Pancreatic Neoplasms 43Stomach Neoplasms 40Sarcoma 37Squamous Cell Carcinoma of Head and Neck 35Triple Negative Breast Neoplasms 31Testicular Neoplasms 29Uterine Cervical Neoplasms 27Esophageal Neoplasms 26Carcinoma, Hepatocellular 26Head and Neck Neoplasms 24Non-Muscle Invasive Bladder Neoplasms 23Small Cell Lung Carcinoma 22Colonic Neoplasms 20Urologic Neoplasms 17Neuroblastoma 17Multiple Myeloma 17Endometrial Neoplasms 17

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Spinocerebellar Degenerations × Genitourinary × Clear all
NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Novartis

Phase 2 Terminated
315 enrolled 73 charts
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡